We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vitamin D Replacement in Statin-Induced Myopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01400009
Recruitment Status : Withdrawn (lack of enrollment)
First Posted : July 22, 2011
Last Update Posted : April 7, 2015
Information provided by (Responsible Party):
Dr. Mark Sherman, McGill University Health Center

July 20, 2011
July 22, 2011
April 7, 2015
October 2010
July 2012   (Final data collection date for primary outcome measure)
lack of need to stop statin medication due to myalgia [ Time Frame: 12 weeks ]
Ability to tolerate a statin at the same dosage that previously caused the individuals to stop due to myalgia
Same as current
Complete list of historical versions of study NCT01400009 on ClinicalTrials.gov Archive Site
reduction of visual analog pain score [ Time Frame: 12 weeks ]
Same as current
Not Provided
Not Provided
Vitamin D Replacement in Statin-Induced Myopathy
Vitamin D Replacement in Statin-Induced Myopathy
Pretreating people with replacement doses of vitamin D will allow them to tolerate Statin medications that have caused muscle pain for them in the past.
Patients who have been unable to tolerate statin medications due to muscle pain will be randomly assigned to receive vitamin D or placebo for 6 weeks before reintroducing their statin medication. The investigators will judge whether vitamin D in the manner administered in the study reduces the myalgia with statins and allows patients to remain on these important medications.
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
HMG COA Reductase Inhibitor Adverse Reaction
  • Drug: Vitamin D (Cholecalciferol )
    10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
    Other Name: DIN number 00821772
  • Drug: Placebo
    Standard Placebo made of Lactose 100 mg
    Other Name: Lactose 100 mg DIN 00501190
  • Placebo Comparator: Placebo
    Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
    Intervention: Drug: Placebo
  • Active Comparator: Vitamin D
    Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
    Intervention: Drug: Vitamin D (Cholecalciferol )
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2012
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • male and female adults
  • identified by their physician as having myalgia with their statin medication.

Exclusion Criteria:

  • Unexplained CK > 4X upper limit of normal, at study entry, or on a statin medication in the past.
  • Severe myositis
  • Consumption in excess of 14 alcoholic beverages per week
  • Situations which will cause difficulty in interpreting the vitamin D and / or PTH.


  • Present consumption of vitamin D supplements > 1000 iu daily
  • Renal impairment (Estimated creatinine clearance < 70 ± 14 mL/min/m2 in Males; and < 60 ± 10 mL/min/m2 in Females)
  • Chronic liver disease or impaired liver function
  • Any contraindication for statin re-challenge Example: rhabdomyolysis or allergy to statins
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr. Mark Sherman, McGill University Health Center
McGill University Health Center
Not Provided
Study Chair: Mark H Sherman, MD,CM McGill University Health Center
McGill University Health Center
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP